Vincerx Pharma (NASDAQ:VINC – Free Report) had its price target reduced by Leerink Partners from $4.00 to $2.00 in a research report report published on Tuesday, Benzinga reports. They currently have an outperform rating on the stock.
Vincerx Pharma Price Performance
VINC stock opened at $0.39 on Tuesday. The business has a fifty day moving average price of $0.67 and a 200 day moving average price of $1.06. Vincerx Pharma has a fifty-two week low of $0.38 and a fifty-two week high of $9.37. The stock has a market capitalization of $11.63 million, a price-to-earnings ratio of -0.30 and a beta of 1.49.
Vincerx Pharma (NASDAQ:VINC – Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.12. On average, equities analysts expect that Vincerx Pharma will post -0.38 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Vincerx Pharma
Vincerx Pharma Company Profile
Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.
Recommended Stories
- Five stocks we like better than Vincerx Pharma
- Transportation Stocks Investing
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- What are earnings reports?
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for Vincerx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vincerx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.